Targeting castration-resistant prostate cancer with a novel RORγ antagonist elaiophylin

• Main Authors: Jianwei Zheng (Author), Junfeng Wang (Author), Qian Wang (Author), Hongye Zou (Author), Hong Wang (Author), Zhenhua Zhang (Author), Jianghe Chen (Author), Qianqian Wang (Author), Panxia Wang (Author), Yueshan Zhao (Author), Jing Lu (Author), Xiaolei Zhang (Author), Songtao Xiang (Author), Haibin Wang (Author), Jinping Lei (Author), Hong-Wu Chen (Author), Peiqing Liu (Author), Yonghong Liu (Author), Fanghai Han (Author), Junjian Wang (Author)
• Format: Book
• Published: Elsevier, 2020-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Prostate cancer (PCa) patients who progress to metastatic castration-resistant PCa (mCRPC) mostly have poor outcomes due to the lack of effective therapies. Our recent study established the orphan nuclear receptor RORγ as a novel therapeutic target for CRPC. Here, we reveal that elaiophylin (Elai),...